NEW STEP BY STEP MAP FOR HOW EFFECTIVE IS PEMBROLIZUMAB

Clinically important immune-mediated hematologic adverse reactions (such as hemolytic anemia, aplastic anemia, immune thrombocytopenic purpura) transpired at an incidence of less than 1% in patients who acquired this drug or were documented with using other PD-one/PD-L1 blocking antibodies.Considering that pembrolizumab is cleared from the circulat